Adaptive randomization versus interim monitoring

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages 969-970

  Freidlin, Boris ^a   Korn, Edward L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE RANDOMIZATION; BAYES THEOREM; CANCER PATIENT; CLINICAL ASSESSMENT; GLIOBLASTOMA; HUMAN; LETTER; OUTCOME ASSESSMENT; PATIENT MONITORING; POWER ANALYSIS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SAMPLE SIZE; SURVIVAL RATE;

BAYES THEOREM; CLINICAL TRIALS, PHASE II AS TOPIC; GLIOBLASTOMA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84875734794     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.0254     Document Type: Letter

References (6)

1. Trippa L, Lee EQ, Wen PY, et al: Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol 30:3258-3263, 2012.
2. Korn EL, Freidlin B: Outcome-adaptive randomization: Is it useful? J Clin Oncol 29:771-776, 2011.
3. Korn EL, Freidlin B: Reply to Y. Yuan et al. J Clin Oncol 29:e393, 2011.
4. Pocock SJ: Interim analyses for randomized clinical trials: The group sequential approach. Biometrics 38:153-162, 1982.
5. Freidlin B, Korn EL: Monitoring for lack of benefit: A critical component of a randomized clinical trial. J Clin Oncol 27:629-633, 2009.
6. Thompson WR: On the likelihood that one unknown probability exceeds another in view of the evidence of the two samples. Biometrika 25:285-294, 1933.